诱导多能干细胞市场规模、分享and Global Trend By Derived Cell Type (Amniotic cells, Fibroblasts, Keratinocytes, Hepatocytes, Others), By Application (Regenerative medicines, Drug development, Toxicity testing, Reprogramming technology, Academic research, Others), By End-user (Hospitals, Education & research institutes, Biotechnological companies) and Geography Forecast till 2030

In the fiscal year of 2018, Fate Therapeutics, one of the experts in induced pluripotent stem cells collaborated with ONO Pharmaceutical Co. Ltd., for the commercialization of two off-the-shelf product candidates related to CAR-T cell. The use of stem cell therapy, as regenerative medicines, has received a huge upsurge as they pose fewer complications and considered a permanent treatment option.

Induced pluripotent stem cells are a type of artificially derived pluripotent stem cells by inducing certain genes. Induced pluripotent stem cells are generated by the introduction of a certain set of specific genes having pluripotency-associated genes into a mature somatic cell. Induced pluripotent stem cells have created new avenues in clinical research, regenerative medicines, and disease modeling. This has also paved the way to numerous mergers and acquisitions and potential pipeline products and patents.

To gain extensive insights into the market,Request for Customization

全球的增长诱导多能干细胞s market is being driven by the active government support through research grants, increased private funding, and shift towards regenerative medicines. In addition, the diversity of donor candidates and increased accessibility to the cell of origin are also factors that are likely to fuel the global induced pluripotent stem cells market in the anticipated years.

However, ethical issues related to the donors, potential risk of tumors are some of the factors that are projected to restrict the growth of global induced pluripotent stem cells market.

Key Players Covered

Some of the major companies that are present in the global induced pluripotent stem cells market are Astellas Pharma Inc., Ncardia, Applied StemCell, FUJIFILM Cellular Dynamics Inc., Axol Bioscience Ltd., Bristol-Myers Squibb Company, R&D Systems Inc., Fate Therapeutics, Evotec AG, ViaCyte Inc., and other players.

SEGMENTATION

SEGMENTATION	DETAILS
By Derived Cell Type	· Amniotic cells · Fibroblasts · Keratinocytes · Hepatocytes · Others
By Application	· Regenerative medicines · Drug development · Toxicity testing · Reprogramming technology · Academic research · Others
By End-user	· Hospitals · Education & research institutes · Biotechnological companies · Others
By Geography	· North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

As of 2018, the regenerative medicines segment is estimated to dominate the global induced pluripotent stem cells market owing to the rise in demand for induced pluripotent stem cells mediated regenerative medicines.

Key Insights

• Regulatory overview for stem cells


• Overview of research grants for induced pluripotent stem cells


• Pipeline analysis


• Overview of advancements in induced pluripotent stem cells


• Key mergers and acquisitions

Regional Analysis

The global induced pluripotent stem cells market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to register a fast growth in induced pluripotent stem cells market in the forecast years owing to the huge investment by private players for research and potential pipeline products. In Europe, the induced pluripotent stem cells market is projected to expand by the end of 2026, due to the active government support and new product launches. In 2018, Ncardia, a company working for drug discovery using stem cell, launched Xpress.4U LightPace Cor.4U, a kit for improving and simplifying the use of optical pacing of cardiomyocytes, a human induced pluripotent stem cell, which expected to favor the induced pluripotent stem cells market in Europe.

Key Industry Developments

• In December 2018, the U.S Food and Drug Administration (FDA) sent a warning to Genetech, Inc. for marketing stem cell therapy without the U.S FDA approval and nonconformity of Good Manufacturing Practice (CGMP).
• In April 2019, The Maryland Stem Cell Research Commission issued its Request for Applications (RFAs) and announced funding opportunities for stem cell research and clinical trials for the fiscal year of 2020.
• In January 2019, STEMCELL Technologies Inc. launched mTeSR Plus, a next-generation induced pluripotent stem cell and Human ES maintenance media.